Depression News

COVID-19 diagnosis did not appear linked to a significant increase in depression and anxiety disorder incidence compared with diagnosis of acute upper respiratory infections, according to a retrospective cohort study conducted in Germany.

Despite an increase in the rate of suicide attempts, use of mental health services by those who attempted suicide within a year of doing so has not increased, per a nationwide cross-sectional study published in JAMA Psychiatry.

Women who viewed themselves as lower in socioeconomic status experienced a higher allostatic load 1 year after giving birth, which may lead to worse health outcomes in the future, according to findings published in Health Psychology.

The prevalence of mental disorders has been on the rise and remains a significant leading cause of disease burden worldwide, according to a 30-year global systematic analysis published in The Lancet Psychiatry.

Two free, brief, single-session online interventions reduced teenagers’ depressive symptoms and hopelessness and increased their ability to create and work towards goals, data showed.

Pacific Neuroscience Institute announced the start of a new clinical trial to assess the safety and efficacy of psilocybin to treat major depressive disorder and has begun participant enrollment, according to a company release.

The FDA has granted an investigational drug designation to PCN-101 ahead of a clinical study to be conducted by atai Life Sciences, according to a company release.

Opioid overdose deaths among older adults increased significantly from 1999 to 2019, especially among non-Hispanic Black men, according to findings published in JAMA Network Open.

Among patients with cardiac disease, nearly 20% used psychotropic medications, and psychotropic medication use was linked to elevated risk for 1-year mortality, researchers reported.

Neuroscience specialty pharmaceutical company OWP Pharmaceuticals Inc. has partnered with Eversana, a provider of global services to the life sciences industry, to launch oral liquid formulations for treating neuroscience disorders.